Skip To Main Content
Neena Brizmohun on Muck Rack

Neena Brizmohun

Verified
London
As seen in: Medtech Insight, Scrip, The Pink Sheet, Generics Bulletin, HBW Insight, In Vivo, Citeline, C+D (Chemist+Druggist)
Deputy editor of Pink Sheet/Scrip/Medtech Insight. Interested in science, pharma and medtech. All views expressed are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neena

Contact Neena, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bio-Based Plastics & Non-PVC Blisters: Sanofi, AZ & Others Float Green Manufacturing Ideas

|
By Neena Brizmohun Verified
| The Pink Sheet Verified
For companies pursuing sustainability-driven changes in drug manufacturing, the European Medicines Agency is planning to develop regulatory guidance in areas where the science is strong enough to act on. Drug regulators are increasingly observing sustainability-driven innovations (Shutterstock) Key Takeaways A two-day meeting held by the European Medicines Agency’s Quality Innovation Group (QIG) explored innovative technologies for advancing sustainability goals in pharmaceutical manufacturing.
Open in Who Shared Issue with article?

NZ Expands Access To Jardiance, Jardiamet, Trulicity & Victoza To 30,000 More T2D Patients

|
By Neena Brizmohun Verified
| The Pink Sheet Verified
Pharmac has lowered the criteria patients must meet to access the funded type 2 diabetes drugs, and because it will be buying a larger volume of the products, it has negotiated new agreements with the suppliers. Pharmac decides which drugs are funded in New Zealand (Shutterstock) Key Takeaways Access in New Zealand is expanding for four funded type 2 diabetes (TD2) drugs – Jardiance (empagliflozin), Jardiamet (empagliflozin with metformin), Trulicity (dulaglutide) and Victoza (liraglutide).
Open in Who Shared Issue with article?

Quotable: Top Experts On Policy Hot Topics

|
By Neena Brizmohun Verified
| The Pink Sheet Verified
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering. “Other countries are eating our lunch in this business because they’ve paid attention to it.” Former acting US Food & Drug Administration Commissioner Janet Woodcock on the need for the US to treat its clinical-site infrastructure as an economic sector with real business incentives and use industrial policy, not an academic approach, to boost it.
Open in Who Shared Issue with article?
See all 1,436 articles